Celator(R) Pharmaceuticals Announces Positive Data From Phase 2 Study of CPX-351 in Acute Myeloid Leukemia
Celator Pharmaceuticals, Inc. today announced positive results from its Phase 2 study of CPX-351 Liposome Injection versus conventional cytarabine and daunorubicin in patients, 60-75 years of age, with untreated acute myeloid leukemia . The primary endpoint of the study, the rate of patients achieving a complete remission with CPX-351 compared to "7+3," achieved statistical significance. In ...
Read more on PR Newswire via Yahoo! Finance
You must log in to post a comment.